Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog

Jason R. Young, Carrie Mcadam-Marx

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Insulin detemir is a long-acting basal insulin approved for use in patients with type 1 (T1DM) or type 2 diabetes (T2DM). Insulin detemir has demonstrated equivalent glycemic control and hypoglycemic risk when compared to insulin glargine, and insulin detemir has generally but not consistently demonstrated less weight gain than insulin glargine in T2DM. The benefits of basal insulin analogs relative to NPH insulin are well recognized, including less FBG variability, lower risk of hypoglycemia, and less weight gain specifically with insulin detemir. However, NPH insulin continues to be widely prescribed, which may be due in part to economic considerations. While NPH insulin generally costs less per prescription, insulin detemir has been shown to be cost effective compared to NPH insulin as well as insulin glargine. Therefore, insulin detemir is an effective option from both clinical and economic perspectives for patients with T1DM or T2DM who require basal insulin to achieve glycemic control.

Original languageEnglish (US)
Pages (from-to)65-80
Number of pages16
JournalClinical Medicine Insights: Endocrinology and Diabetes
StatePublished - 2010
Externally publishedYes


  • Basal insulins
  • Diabetes mellitus
  • Insulin detemir

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog'. Together they form a unique fingerprint.

Cite this